SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-046414
Filing Date
2023-12-28
Accepted
2023-12-28 17:25:20
Documents
13
Period of Report
2023-12-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48658
  Complete submission text file 0001493152-23-046414.txt   277778

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bfri-20231221.xsd EX-101.SCH 3976
3 XBRL DEFINITION FILE bfri-20231221_def.xml EX-101.DEF 27432
4 XBRL LABEL FILE bfri-20231221_lab.xml EX-101.LAB 37886
5 XBRL PRESENTATION FILE bfri-20231221_pre.xml EX-101.PRE 26049
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6275
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

IRS No.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 231523524
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)